Capricor Therapeutics Inc... (CAPR)
| Bid | 13.45 |
| Market Cap | 619.53M |
| Revenue (ttm) | 31.92M |
| Net Income (ttm) | -46.88M |
| EPS (ttm) | -1.02 |
| PE Ratio (ttm) | -13.36 |
| Forward PE | -18.15 |
| Analyst | Buy |
| Ask | 13.9 |
| Volume | 1,295,684 |
| Avg. Volume (20D) | 1,146,215 |
| Open | 15.37 |
| Previous Close | 15.38 |
| Day's Range | 13.27 - 15.23 |
| 52-Week Range | 3.52 - 23.40 |
| Beta | 4.09 |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Ph...
Analyst Forecast
According to 7 analyst ratings, the average rating for CAPR stock is "Buy." The 12-month stock price forecast is $32.5, which is an increase of 138.53% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Deramiocel's Promise Brightens Capricor's Outlook, With Strings AttachedCapricor Therapeutics is advancing deramiocel, an allogeneic cell therapy for DMD-related cardiomyopathy, with a rolling BLA submission and potential FDA approval by 2025. Deramiocel showed significan...
2 months ago · seekingalpha.com
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA SubmissionCapricor Therapeutics initiated its rolling BLA submission for Deramiocel to treat Duchenne Muscular Dystrophy Cardiomyopathy, with completion expected before the end of 2024. The company presented pr...